Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $143 to $144.
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $143 to $144.